Global proteomics (Cell, Tissue, blood proteome) Label-free analysis based on data-independent acquisition (DIA). Our industry-leading protein analysis of non-depleted plasma can result in 1,300 protein identifications in one-hour per single sample. Our isotope-labeling enables a sample-to-sample comparison analysis in protein quanti�cation. Bertis labeling quantification and advanced fractionation technology enable industry-leading protein quantification analysis in cell or tissue samples. Our phospho/glyco proteomics ensures high-quality post-translational modification (PTM) analysis of proteins, providing an optimized solution for biomarker discovery and mechanism of action analysis. Our bioinformatics analysis provides your research needs from basic analysis of protein composition and quantiy cation to in-depth systems biology analysis. We provide analysis services that meet our customer's needs through continuous communication and interaction.
Companion Diagnostics (CDx) provide a companion diagnostic solution through pathway analysis based on RNA and protein quantification information respective to subtypes from each diseases. For precision medicines developed based on multi-omics analysis, biomarkers can be used to identify target patients in advance. Global pharmaceutical companies are active in the use of companion diagnostics as a key strategic tool in clinical development programs. PASS provides solutions for the entire process from discovery of drug candidates to non-clinical to clinical trials through pan-omics technology. Bertis has array of innovative and reliable technology to increase the safety and efficacy of an investigational drug across the clinical research landscape, including solutions for the discovery of biomarkers for companion diagnostics and the determination of clinical targets through functional analysis.
Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood. High diagnostic accuracy : Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI. Convenience : No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling Efficiency: Provides diagnosis opportunities to more people in situations where personnel and devices are limited
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
PC-PASS Protein Characterization Analysis Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
I'm CKSONG, CEO of SEIL CO., LTD Our company is exporting and growing mainly in PCB, PCB assembly, electronics, plastic resin, injection, and mold business Our-centered PCB, PCBA, plastic resin, and injection products have advantages in quality and reliability that have been verified during delivery to large Korean companies such as Samsung and LG. We hope that our reliable quality products and constant desire to pursue a sustainable business will meet with you to become a mutually developing business partner to pioneer the global market It is supplying difficult quality review and price review procedures to mid-sized and large Korean companies such as Samsung and LG at an annual amount of 50 to 65 billion KRW In addition, we are constantly growing in the process of winning orders with global companies overseas, and we are working on PCBA (PCB Assembly), OSP, and semiconductor parts as well as PCB, by combining our technology with the requirements of customers for each item such as PCB Single, Double, and MLB (over 4-24 layers) We hope to make a positive business by contacting you from time to time by emailing you with requirements such as your desired specification and PCB drawing file
Safety shoes, metal craft products, ducting coolers, moringa products, complete car care products, cleaning, polishing, rubbing compounds ,automotive aerosols, complete range..
Ptfe molded sheet, ptfe skived sheet/film, ptfe rod, ptfe tube, ptfe finshed products, ptfe compounds(bronze/carbon/glass fiber/mos2), pfa welding rod, ptfe expanded sheet/tape.Export
Rubber sheets, conveyor belts, rubber molded products, rubber compounds, rubber extruded products, coated fabrics, inflatables, waterproofing epdm rubber membrane, rubber mats, rubber flooring, industrial rubber products.Exporter
Formaldehyde, moulding compounds (urea and melamine), form urea, dry and liquid glues, urea formaldehyde powder resin, glaze, muf, phenolic resins, formica, lpl, snf, and sulfuric acid.manufacturer
Scrap tires, scrap tire wires, scrap nylon tire codes, scrap/rejected bead wires, scrap curing bags, scrap bladders, scrap rubber compound, rubber related waste.
Pvc compounds and pvc/rubber building materials,wall panels, skirting boards, mouldings, flooring, roofing, gardeningrubber gaskets,pvc interlocking tile/rubber flooring mat proposal.
T bars ceiling grid, ceiling tiles (calcium silicate ceiling tiles, gypsum ceiling tiles, mineral fiber ceiling tiles, metal ceiling tiles), partition frame, partition boards (calcium silicate boards & fiber cement boards, gypsum boards), fiberglass wool insulation / rock wool insulation, all purpose joint compound/ skim coat compound, flooring series (spc, wpc etc.).
AZO AUTO is the highest quality car chemistry products for professional vehicle maintenance. The main activity of AZO PRODUCTS is the reduction of nitrogen oxide emissions from vehicles and factories. We offer our customers products that meet the highest pollution prevention standards, helping them not only to meet European environmental obligations, but also to be socially responsible. AdBlue�® is a high-purity (32.5%) urea solution used to reduce nitrogen oxide (NOx) emissions from vehicles with SCR technology. Reduces emissions of harmful particles nitrogen oxides; Optimizes engine performance; Used in diesel engines with SCR (selective exhaust system); Meets European standards; Manufactured according to the requirements of the German Automobile Industry Association, in accordance with the strict ISO 22241-1 / -2 / -3 / -4 / -5 standard; A quality passport is issued for each production batch;
Balract is composed of formic acid ,benzoic acid and fumaric acid . with advanced embed technique, Baltract released H+ and kill pathogenic bacteria in gastrointestinal tract .The organic acids with low such as formic acid preferentially release H+, providing acidifier that promote digestion and inhibit bacteria in the gut
Drinkic is a blue liquid composed of organic acids preparation for drinking water , Buffering ensures that pH remains stable after a thousandfold dilution . Drinkic in drinking water can promote the growth performance by enhancing digestion and inhibiting pathogenic bacteria In addition ,It maintains gut flora balance It improves water quality and prevents biofilm formation
